{"schema_version":"secwatch.filing_event.v1","accession":"0001816736-25-000006","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.097135+00:00","generated_at":"2026-05-17T18:08:09.284310+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Disc Medicine Q2 net loss $55.2M; on track for bitopertin NDA in October 2025","bullets":["Cash of $650.0M as of June 30, 2025; expected to fund operations into 2028.","NDA submission for bitopertin in EPP under accelerated approval planned for October 2025 after positive pre-NDA meeting.","Phase 2 data from DISC-0974 in MF anemia and multiple-dose data from Phase 1b in NDD-CKD anemia expected Q4 2025.","Initiated Phase 2 study of DISC-3405 in polycythemia vera; initial data anticipated in 2026.","Appointed Nadim Ahmed (Cullinan Therapeutics CEO) to Board of Directors in July 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001816736-25-000006","json":"https://secwatch.observer/filing/0001816736-25-000006.json","markdown":"https://secwatch.observer/filing/0001816736-25-000006.md","text":"https://secwatch.observer/filing/0001816736-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000181673625000006/0001816736-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000181673625000006/iron-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:08:09.284310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}